8-K: VSee Health Faces Nasdaq Delisting, Moves to OTC

VSee Health, Inc. received a Nasdaq delisting determination due to delayed financial filings, with trading suspended on August 14, 2025, and plans to appeal.

Summary

• VSee Health, Inc. (VSEE) received a letter from Nasdaq on August 5, 2025, denying its request to continue listing.
• The delisting is due to non-compliance with Nasdaq Listing Rule 5250(c)(1) for failing to timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and its Quarterly Report on Form 10-Q for the period ended March 31, 2025.
• Trading in the company's common stock and warrants (VSEEW) will be suspended on Nasdaq at the open of trading on August 14, 2025.
• The company intends to submit a request for reconsideration to the Nasdaq Listing and Hearing Review Council.
• Following suspension, the common stock and warrants are expected to begin trading on the OTC Markets system under their current symbols (VSEE and VSEEW) starting August 14, 2025.

Sentiment

Score: 2

Explanation: The company faces delisting from Nasdaq due to significant financial reporting compliance failures, leading to trading suspension and a move to the less liquid OTC Markets, which is a severe negative event for shareholders and company reputation.

Negatives

• Nasdaq denied the company's request to continue listing.
• Trading in common stock and warrants will be suspended on Nasdaq at the open of trading on August 14, 2025.
• Expected delisting from Nasdaq.
• Failure to timely file Annual Report on Form 10-K for the fiscal year ended December 31, 2024.
• Failure to timely file Quarterly Report on Form 10-Q for the period ended March 31, 2025.
• Potential for a very limited market on OTC Markets, making it difficult for stockholders to sell shares.
• Trading price of common stock and warrants may be adversely affected.

Risks

• There is no assurance that the request for reconsideration or appeal to the Nasdaq Listing and Hearing Review Council will be successful.
• There is no assurance that the company will be able to demonstrate compliance with applicable continued listing requirements if permitted to continue trading on Nasdaq.
• Once delisted, there may be a very limited market for the company's common stock and warrants.
• Stockholders and warrant holders may find it difficult to sell their shares and warrants.
• The trading price of the common stock and warrants may be adversely affected.
• Uncertainty regarding the company's ability to file the Form 10-K and/or Form 10-Q.
• Uncertainty regarding meeting Nasdaq compliance standards.

Future Outlook

The company intends to appeal the delisting decision and expects to trade on the OTC Markets if the appeal is unsuccessful. There is no assurance of success in regaining Nasdaq compliance or meeting continued listing requirements.

Management Comments

• The Company intends to submit a request for reconsideration to the Staff and to otherwise appeal the determination to the Nasdaq Listing and Hearing Review Council (the Council), as necessary.
• The Company expects that its common stock and warrants will begin trading under their current trading symbols, VSEE and VSEEW, respectively, on the OTC Markets system starting on the date trading of the Companys common stock is suspended, August 14, 2025.
• The Company remains committed to regaining compliance with all applicable Nasdaq requirements and will continue to keep shareholders informed of material developments as they occur.

Industry Context

Delisting from a major exchange like Nasdaq to OTC Markets typically signals significant operational or financial distress for a company, often leading to reduced liquidity and investor confidence. This event places VSee Health in a less favorable position compared to its Nasdaq-listed peers in the telehealth sector.

Comparison to Industry Standards

• Maintaining timely financial filings (10-K, 10-Q) is a fundamental compliance requirement for all publicly traded companies on major exchanges like Nasdaq. VSee Health's failure to meet this standard puts it significantly below industry best practices.
• Companies like Teladoc Health (TDOC) or Amwell (AMWL), which operate in similar telehealth sectors and are listed on major exchanges, consistently meet their filing obligations, providing transparency and maintaining investor trust. VSee Health's situation contrasts sharply with these peers.
• Moving to the OTC Markets typically results in lower trading volume and less analyst coverage compared to Nasdaq, impacting market visibility and valuation, unlike well-established telehealth companies that benefit from major exchange listings.

Stakeholder Impact

• Shareholders/Warrant Holders: Will experience trading suspension on Nasdaq, potential difficulty selling shares/warrants on OTC Markets, and likely adverse impact on trading price. Reduced liquidity and transparency.
• Company Management: Faces significant challenge in resolving compliance issues and appealing delisting, with potential reputational damage.
• Employees: No direct impact mentioned, but company instability could affect morale or future prospects.
• Customers/Suppliers/Creditors: No direct impact mentioned, but delisting can signal financial instability, potentially affecting business relationships.

Next Steps

• Submit a request for reconsideration to the Nasdaq Staff.
• Appeal the determination to the Nasdaq Listing and Hearing Review Council, if necessary.
• Trading of common stock and warrants on OTC Markets system starting August 14, 2025.
• Company will continue to keep shareholders informed of material developments.

Key Dates

Recommendation

The delisting from Nasdaq due to persistent failure to meet financial reporting obligations is a severe negative event. It signals significant operational and governance issues, leading to a move to the less liquid OTC Markets. This will likely result in a substantial decrease in share price, reduced investor confidence, and difficulty for shareholders to exit their positions. The uncertainty of a successful appeal further exacerbates the risk.

Keywords

VSee Health, VSEE, VSEEW, Nasdaq, delisting, OTC Markets, Form 10-K, Form 10-Q, financial reporting, compliance, suspension, common stock, warrants